6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT
Subaward Agreement with New York University Executed by Clene Inc.
Reports Full Year 2025 Financial Results And Recent Operating Highlights
Issues Stockholder Letter Highlighting Upcoming CNM-AU8® 2026 Catalysts
Announces Registered Direct Offering of Over $28 Million
Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
Investor Presentation
REPORTS Third QUARTER 2025 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Specialized Disclosure Report